

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number  
**WO 2004/034820 A2**

(51) International Patent Classification<sup>7</sup>: **A23L 1/30**

(21) International Application Number:

PCT/EP2003/014777

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0212887	16 October 2002 (16.10.2002)	FR
60/441,762	23 January 2003 (23.01.2003)	US

(71) Applicants (*for all designated States except US*):  
**L'OREAL** [FR/FR]; 14, rue Royale, F-75008 Paris (FR).  
**NESTEC S.A.** [CH/CH]; Avenue Nestlé 55, CH-1800  
Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DURANTON**,  
Albert [FR/FR]; 55b, rue du Tir, F-78600 Maisons-Lafitte  
(FR). **MALNOE**, Armand [FR/CH]; CH-1041 Mon-  
taubion Chardonney (CH).

(74) Agents: **VAILLANT**, Jeanne et al.; Ernest Gutmann-Yves  
Plasseraud S.A., 3, rue Chauveau-Lagarde, F-75008 Paris  
(FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COSMETIC COMPOSITION FOR PREVENTING AND/OR CORRECTING THE FUNCTIONAL DISORDERS OF  
THE PILO-SEBACEOUS UNIT OF MAMMALS

(57) Abstract: The present invention relates to a cosmetic composition suitable for administration by the oral route and designed to prevent and/or correct the functional disorders of the pilo-sebaceous unit of mammals, in particular by combating the cutaneous activation of the androgens over the course of time, said composition containing polyunsaturated fatty acids, flavonoids and stilbenes. The objects of the invention are also a cosmetic method using such a composition, as well as the use of such a composition for the preparation of a food supplement designed to prevent and/or correct the functional disorders of the pilo-sebaceous unit of mammals, especially for the treatment of oily and/or hyper-seborrheic skin and/or scalp, thin hair, hypertrichosis and/or alopecia in human.

WO 2004/034820 A2

**COSMETIC COMPOSITION FOR PREVENTING AND/OR CORRECTING  
THE FUNCTIONAL DISORDERS OF THE PILO-SEBACEOUS UNIT  
OF MAMMALS**

The present invention lies within the scope of the development of new  
5 products and treatment procedures for cosmetic purposes intended for  
human and animals. In particular, the invention relates to the field of  
cosmetic products which can be administered by the oral route, such as food  
supplements.

Thus, the object of the invention is a cosmetic composition suitable for  
10 administration by the oral route and intended to prevent and/or correct the  
functional disorders of the pilo-sebaceous unit of mammals, in particular by  
combating the cutaneous activation of the androgens in the course of time,  
said composition comprising polyunsaturated fatty acids, flavonoids and  
stilbenes.

15 The present invention also relates to a cosmetic method using such a  
composition to prevent and/or correct the functional disorders of the pilo-  
sebaceous unit of mammals.

The hairs of mammals in general, the hairs and hair of human in  
particular, are keratinised filaments of variable length.

20 In the remainder of the text the term "hair" will designate both body  
hairs of human and animals, and the hair of human. Consequently, the  
adjective "hairy" will refer to hairs as such or to hair or also to both. In every  
case, the sense to be given to this adjective will emerge in a clear and  
unambiguous manner from the text.

25 In the sense of the present invention, unless otherwise stated the term  
"human" is meant to designate both man and woman.

The hairs comprise a fixed part or root, implanted in an invagination of  
the epidermis, the hairy follicle and a free part or stem, more or less tapering  
at its extremity. The root of the hair adheres to the hairy follicle and forms, at

its base, a bulb emptied at its centre where is lodged the dermal papilla rich in capillaries with a nutritive function.

At the base of each hair a sebaceous gland is appended. This latter secretes a semi-liquid fatty substance, the sebum, a mixture of fatty acids, triglycerides, cholesterol, cholesterol derivatives and cell debris (Stewart, M. E. Semin. Dermatol 11, 100-105 (1992)). In human, for example, the sebaceous glands cover the whole of the body with the exclusion of the palms of the hands and the soles of the feet. Besides the scalp, these glands are particularly widespread around the nose, the mouth, on the forehead, the cheek, the chin and the neck, where their density may vary between about 400 and 900 glands per square centimetre.

The sebum, secreted by the sebaceous gland at the level of the hairy follicle, lubricates the surface of the skin, the hairs and the hair. It forms a slightly acidic fatty film, designed to protect the skin against external aggressions and dehydration, and does so owing to its antiseptic properties, its "barrier" function towards the exterior and its capacity to retain water.

However, when the sebum is secreted in excessive quantities, the skin, the hairs and the hair assumes a glossy sheen which can reveal itself as particularly unaesthetic. One then speaks of "impairments", "disorders", "disturbances" or functional disorders of the pilo-sebaceous unit.

In the present context, it is understood that the terms pilo-sebaceous "unit", "organ" and "apparatus" can be used interchangeably to designate the whole constituted by the hairy follicles and the associated sebaceous glands.

The disorders mentioned above may sometimes reveal themselves to be severe, a simple sebaceous hypersecretion or seborrhea, capable of developing to quite extensive forms of alopecia.

In the mammals, the development and function of the sebaceous glands are regulated by complex mechanisms involving the endocrine system (Mercurio et al.; J. Gend Specif Med 2000 May-Jun; 3 (4): 59-64).

The endocrine system groups together the endocrine glands, the products of secretion of which, the hormones, are discharged directly into the blood.

Chemical messengers of the organism, the hormones thus produced  
5 usually act on an organ or a specific target tissue.

The hormones do not constitute a homogeneous chemical class. In fact, under this generic term, are grouped together compounds of structure as different as proteins, peptides, steroids, aromatic compounds and amines.

10 In particular, the sex hormones such as testosterone, the estrogens or progesterone belong to the family of the steroids, hormonal compounds derived from cholesterol. These include in particular the male sex hormones, the androgens.

It has been observed that the pilary density of mammals is modified  
15 over the course of time.

As regards the hair, the number and diameter of the capillary stems diminish with age. Certain masculine subjects even go so far as to develop andro-genetic alopecias. Furthermore, these adverse changes of the hair are sometimes accompanied by a modification of the state of the scalp, such as  
20 an overabundant production of sebum.

In women, age may cause to appear anomalies of pilosity, for example an excess of hairs on the legs, the arms or the growth of hairs at the level of the beard or the moustache.

Studies have shown that active hormones, in particular sex steroids,  
25 are formed by conversion of inactive precursors in the peripheral target tissues, such as the mammary glands, the prostate, the uterus, the bones and the skin. Thus, the androgenic and estrogenic hormones exert an activity in these tissues.

As a result, the adverse changes in the pilo-sebaceous unit mentioned  
30 above are due essentially to an abnormal metabolism of the steroid hormones, in particular of the androgens (Labrie et al.; Horm Res 2000;

54(5-6): 218-29). More exactly, said adverse changes are the result of a local activation, i.e. cutaneous, of the androgens, and in particular of testosterone during the course of time (Labrie et al.; Horm Res 2000; 54 (5-6): 218-29; Example 1, *infra*).

5       At present, the functional disorders of the pilo-sebaceous apparatus of mammals remain difficult to treat from the cosmetic point of view. On the one hand, the topical route proves to be poorly adapted in as much as the surfaces to be treated are most often large and require an at least daily frequency of treatment. On the other hand, the products likely to be  
10 administered by the oral route and which are currently available on the market exhibit non-negligible side effects, especially sexual. Their use consequently requires a regular control and close supervision by a medically qualified personnel.

      Consequently there exists a need for products active against the  
15 above-mentioned disturbances, said products needing to be adapted to an administration by the oral route and devoid of side effects.

      The objective of the present invention is precisely to fulfil such a need.

      The invention relates in fact to a cosmetic composition useful for the prevention and/or the correction of the functional disorders of the pilo-  
20 sebaceous unit of mammals, said composition being designed for administration by the oral route and comprising polyunsaturated fatty acids, flavonoids and stilbenes.

      Such a composition makes it possible to combat the cutaneous activation of the androgens, including testosterone and the adrenalian  
25 androgens, during the course of time.

      The compositions according to the invention are especially useful for the treatment of oily and/or hyper-seborrheic skin and/or scalp, thin hair, hypertrichosis or excess of hairs and/or alopecia, in human.

      In a preferred manner, the composition according to the invention is a  
30 food or nutritional supplement.

In the context of the present invention, the term "mammal" must be understood in conformity with the general usual acceptation. This notwithstanding, the term "mammals" in the sense of the invention advantageously targets domestic animals and/or human beings.

5 In a preferred manner, the polyunsaturated fatty acids and/or the flavonoids and/or the stilbenes contained in a composition according to the invention are of natural origin. In a still more preferred manner, the set of these compounds is of natural origin. By "natural origin" is meant a compound in the pure state or in solution at variable concentrations, said  
10 compound being obtained by various extraction processes known to the specialist, starting from a natural element, for example a plant or an animal. More preferably, all the compounds are extracted from compounds which are usually used as food.

The polyunsaturated fatty acids are essentially polyethylenic acids, i.e.  
15 comprising at least two carbon double bonds. In fact, there are in nature few polyunsaturated fatty acids containing carbon-carbon triple bonds.

According to a first feature of the composition in conformity with the invention, the polyunsaturated fatty acids that it contains are called essential fatty acids. These fatty acids, although they cannot be synthesized by the  
20 mammals themselves, are essential to the normal metabolism of said mammals (growth, development and integrity of the skin, reproductive functions, in particular gestation and lactation...). The essential fatty acids must be taken with the food.

The polyunsaturated fatty acids originating in the food are defined by  
25 the length of the carbon chain and the position of the double bonds. Thus they are classed in two groups, without metabolic conversion nor functional substitution being possible from one to the other, said groups being distinguished by the position of the unsaturation closest to the terminal methyl group. These groups are conventionally called n-3 (or  $\omega$ 3 or "omega-  
30 3") and n-6 (or  $\omega$ 6 or "omega-6"). As examples, fatty acids of group n-3 are  $\alpha$ -linolenic acid [18 (number of carbon atoms): 3 (number of unsaturations)

n-3] and stearidonic acid (18:4 n-3). Fatty acids of group n-6 are, for example, linoleic acid (18:2 n-6) and  $\gamma$ -linolenic acid (18:3 n-6).

Of the essential fatty acids suitable for the preparation of a composition according to the invention, the specialist will preferably select  
5 polyunsaturated fatty acids belonging to group n-6. In particular,  $\gamma$ -linolenic acid will be advantageously selected.

As indicated above, the fatty acids contained in a composition in conformity with the invention are preferably extracts of animal or plant natural sources. In this respect black currant pip oil, evening primrose oil; borage  
10 and hemp may be mentioned as oils of plant origin, the extracts of spirulin, in particular *Spirula maxima* and *S. platensis*, and the oils of fishes and those derived from sea products as oils of animal origin. Obviously, these oils can be used alone or in the form of mixtures. Preferably, the specialist will select the black currant pip oil as source of polyunsaturated fatty acids.

15 According to another feature of the composition in conformity with the invention, the latter contains flavonoids, in particular isoflavonoids.

The flavonoids are polyphenols which, depending on their structure and the degree of oxidation to which they are subjected, are divided into flavonols, flavones, catechins, proanthocyanidines and their analogues and  
20 derivatives.

The natural sources of flavonoids are mainly plants, in particularly the representatives of the families of the Umbelliferae, Rosaceae, Leguminosae and other compounds. Flavonoids are also found in products derived from the vine and tea.

25 The isoflavonoids constitute a sub-class of the flavonoids. They are formed of a 3-phenylchromane skeleton which can bear varied substituents at different levels of oxidation. Contrary to the flavonoids, the isoflavonoids are present in only a very limited number of plants.

In fact, the term "isoflavonoid" designates a set of classes of  
30 compounds, including the isoflavones, the isoflavanones, the rotenoids, the pterocarpanes, the isoflavanes, the isoflavan-3-enes, the 3-arylcoumarines,

the 3-aryl-4-hydroxycoumarins, the coumestanes, the coumaronochromones, the  $\alpha$ -methyldesoxybenzoins or the 2-arylbenzofurans. For a complete review of the isoflavonoids, the methods of their analysis and their sources, the specialist will be able to refer to Chapter 5 entitled "Isoflavonoids" of the monograph "The Flavonoids" (Dewick, P.M. Harbone Ed. pp. 125-157 (1988)).

Isoflavonoids particularly suited to being implemented in the context of the present invention are, for example, daidzein, formononetin, cuneatin, genistein, isoprunitin and prunitin, cajanin, orobol, pratensein, santal, junipegein A, glycitein, afrormosin, retusin, tectorigenin, irisolidon, jamaicin as well as their analogues and derivatives.

Of the isoflavonoids used in the context of the invention, preference will be given to the isoflavones, and in an even more preferred manner to the simplest aglycone forms, including daidzein, genistein and their mixture. These two compounds are particularly present in the extract of soja *Glycina max*.

According to another specific embodiment of the invention, two different sources of extracts which are rich in flavonoids are used, one rich in procyanidines and another one rich in isoflavonoids.

According to another feature of the composition in conformity with the invention, the latter contains stilbenes, in particularly hydroxystilbenes.

The stilbenes, possibly glycosylated, are produced by plants, essentially the spermatophytes, and belong to the class of antibiotic molecules called phytoalexins. Of these mention may be made of resveratrol or 3, 5, 4'-trihydroxystilbene.

Resveratrol is produced by many fruits and plants, in a simple (trihydroxystilbene) or glycosylated form (piceid, polydatin or 4',5-dihydroxystilbene-3-O- $\beta$ -mono-D-glucoside, for example). Simple and glycosylated forms of resveratrol are particularly present in the skin of the grape (Vrhovsek et al. Am J Enol Vitic 48 (2)(1997)), or also in *in vitro* culture supernatants of *Vitis vinifera* (Teguo et al. J Nat Prod 61, 655-657 (1998)).

Cosmetic compositions comprising resveratrol have already been described in the context of the control of signs of skin ageing (WO 99/04747 in the name of Unilever, N.V.). Similarly, a procedure has been described for obtaining ester derivatives of resveratrol and the use of these latter in  
5 cosmetic compositions as precursors of resveratrol (WO 99/03816 in the name of Caudalie). Finally, the applicant has described the advantageous use of glycosylated hydroxystilbene derivatives, more stable and more soluble than the corresponding hydroxystilbenes, as precursors of these latter for the preparation of cosmetic, dermatological or pharmaceutical  
10 compositions designed for a topical application (French patent application No. 0010008 Filed on 28 July 2000).

The hydroxystilbenes may be extracts of plants or plant materials containing them which include the following plant families, cited purely as illustrations: Vitaceae, Umbelliferae, Myrtaceae, Dipterocarpaceae,  
15 yperaceae, Gnetaceae, Leguminosae, Graminaeae, Sericeae, Haemodoraceae, Muaceae, Polygonaceae, Pinaceae, Cupressaceae, Cesalpiniaceae, Poaceae, Solanaceae. In particular, they can be isolated from tissues of *V. vinifera* or *Polygonum cuspidatum*. The specialist will select grape skin or products derived from the grape such as wine as  
20 preferred sources of hydroxystilbenes. For example, grape extracts can be obtained from the marc of grapes, the pips and/or seed envelopes and/or possibly the stalks of grapes.

Thus, in the present context, extracts of red wine or grape pips, rich in polyphenolic compounds of the resveratrol type and proanthocyanidines may  
25 advantageously be used.

According to one embodiment of a composition in conformity with the invention, the latter is packaged in the form of unit doses adapted to administration by the oral route, said administration being carried out at the rate of 1 to 6 doses or units per day. Preferably, the dose of 3 units/day is  
30 recommended.

The daily doses recommended in conformity with the invention are included between 0.5 and 2600 mg/day, and preferably between 5 and 1200 mg/day of polyunsaturated fatty acids, between 0.5 and 1000 mg/day, and preferably between 20 and 300 mg/day of flavonoids, and between 0.5 and  
5 1000 mg/day, and preferably between 10 and 200 mg/day of stilbenes.

The compositions of the invention can be taken for several days, weeks or months. The period of treatment can be repeated many times in a year and can be even continuous. Indeed, the active extracts used in the compositions originates from usual food sources for human or animal, and  
10 does not lead to risks of toxicity.

These recommended daily doses are such that a composition according to the invention comprises the following quantities in weight per 1 g dose unit:

- 15 - from 0.1% to 99%, preferably from 5 to 60% and still more preferred from 10 to 40% of polyunsaturated fatty acids;
- from 0.1% to 99%, preferably from 5 to 60% and still more preferred from 10 to 30% of flavonoids; and more preferably from 20 to 30%;
- 20 - from 0.1% to 99%, preferably from 5 to 40% and still more preferred from 10 to 25 % of stilbenes .

The composition according to the invention may be presented in all possible imaginable galenical forms, provided that these latter are adapted to administration by the oral route. Thus may be mentioned as non-limiting examples, a drinkable solution, a syrup, a tablet, a coated tablet, a gelatine  
25 capsule, or even an enriched foodstuff such as a biscuit, a nutrient bar or powder, possibly compacted. The powders may be diluted in water, soda, milk products or soja derivatives or be incorporated into bars or biscuits, for example. Preferably, the composition according to the invention is a solid composition, and for example, a tablet, a coated tablet, a gelatine capsule, or

even an enriched foodstuff such as a biscuit, a nutrient bar or powder, possibly compacted.

According to another embodiment of a composition in conformity with the invention, the latter comprises, in addition to polyunsaturated fatty acids, flavonoids and stilbenes, at least one excipient appropriate for an oral administration. In one specific embodiment, the composition of the invention consists of polyunsaturated fatty acids, flavonoids stilbenes, and excipients appropriate for an oral administration. In this respect, the formulation agents, adjuvants and excipients for oral compositions, in particular for foodstuff supplements are known to the specialist. Among others and in a purely illustrative manner, mention may be made of lubricants such as magnesium stearate, products for instantaneous solubilization, gelling agents, thickeners, moisteners, fatty and/or aqueous compounds, preservatives, texturizing, flavouring and/or glazing agent, anti-oxidants and colouring agents usual in the food sector.

The composition according to the present invention may in addition contain one or more vitamins and/or trace elements. As a guide, the following active compounds may, for example, be used alone or in combination: zinc and its salts including zinc sulfate and zinc glucanate, the vitamins B5, B6, B8, C,E or PP,  $\beta$ -carotene and the carotenoids, garlic extracts particularly in the form of allyl sulfide or ajoen, selenium, curcumine, the curcuminoids, niacin, lithospermic acid and adenosine. It is understood that the specialist will select such active compounds and, if necessary, will combine them so as to improve the effects expected of the composition which is the object of the invention, and avoid the inhibition or attenuation of the desired activity of interest.

In one specific embodiment, the composition does not contain any Lotus (Nelumbo) extract, and especially, the composition does not contain any active substance of the Lotus, selected among methyltransferases, ascorbic acid, glutathione and dopamine agonists.

In another specific embodiment, the composition does not contain any DHEA or an analogue thereof.

In another specific embodiment, the composition of the invention does not contain panthetin.

5 In another specific embodiment, the composition of the invention does not contain milk or compounds extracted from milk.

The objective of the invention is also a cosmetic method for the prevention and/or the correction of the functional disorders of the pilo-sebaceous unit of mammals, particularly of human beings and domestic  
10 animals, and more specifically for the treatment of oily and/or hyper-seborrheic skin and/or scalp, thin hair, hypertrichosis or excess of hairs and/or alopecia, said process consisting of administering by the oral route a composition such as described above. More preferably, the cosmetic method is applied to human.

15 Finally the present invention relates to the use of a composition such as referred to above, containing polyunsaturated fatty acids, flavonoids and stilbenes for the preparation of a foodstuff supplement designed to prevent and/or correct the functional disorders of the pilo-sebaceous unit of mammals, in particularly of human beings and domestic animals.

20 Thus, the invention concerns the use of a composition as above-defined in a cosmetic method intended for increase the density of keratinic fibers and especially hair, and/or reduce the heterogeneity of their diameter and/or improve their growth, and/or prevent and/or reduce and/or delay hair loss.

25 As used herein, the term "heterogeneity of hair diameters" refers to a significant variation in the hair diameter in a specific region of the scalp; some hair having a physiological diameter in the range of 100  $\mu\text{m}$ , and others, in the nearest proximity of those hair, having a reduced diameter (thin hair). Thus, by "reducing heterogeneity of the diameter", it is meant  
30 increasing the diameter of thin hair.

By "increasing the density", it is meant increasing the number of keratinic fibers, hairs or eyelash per square centimetre of skin or scalp.

The present invention is illustrated, without being limited, by the following Figures:

Figure 1: development of the size of the costo-vertebral organ (hereafter CVO) of the hamster under the effect of a topical application of testosterone (illustration of the "testosterone effect").

D50 corresponds to the start of the daily applications of testosterone to the right CVO.

Figure 2: inhibition of the "testosterone effect" by the polyunsaturated fatty acids, flavonoids and stilbenes, alone or in combination.

- controls
- ◆--- black currant pips
- 15 ---▲--- soja extract enriched with 40% content of isoflavones
- wine concentrate
- Φ--- combination

The characteristics of the invention mentioned above, as well as others not mentioned in detail in the foregoing, will emerge clearly in the light of the following examples. These examples are designed to illustrate the object of the invention, without limiting its scope.

## EXAMPLES

### Example 1: Demonstration of the effect of a topical application of testosterone to the pilo-sebaceous unit – in vivo test:

5

#### 1-A- Principle of the CVO test:

The CVO of the hamster is a cutaneous region rich in pilo-sebaceous units.

The CVO test consists of determining the anti-androgenic action of  
10 different compounds on the CVO, i.e. of determining whether said compounds prevent the action of testosterone (Liao S et al. Arch Dermatol Res 293(4), 200-205 (2001)).

#### 15 1-B- Results of the control experiments: observation of the "testosterone effect":

Figure 1 shows the change in the size of the CVO in control animals which have not received any food supplement, in the case of topical testosterone application. More exactly, Figure 1 shows the surface area difference between the right CVO, that has received testosterone, and the  
20 left CVO (negative control). Consequently, this figure illustrates the "testosterone effect".

As from the fiftieth day (dotted arrow), testosterone was applied daily to the right CVO.

As Figure 1 shows, testosterone induced over the course of time an  
25 increase in the size of the right CVO compared with that of the left CVO.

**Example 2: Demonstration of the inhibition of the "testosterone effect"**  
**by a composition in conformity with the invention:**

**2-A- Products tested:**

5 The following products were used in the context of the *in vivo* CVO test such as defined above. These products were tested as food supplements, alone or in combination.

- 10 (a) the natural aroma of red wine rich in resveratrol (stilbenes) and proanthocyanidines (flavonoids) in the proportion of 0.11 g in 43 g of food (18% of polyphenols);
- (b) a soja extract containing 40% of isoflavonoids, in a proportion of 0.02 g of extract in 44 g of food (40% of isoflavones);
- (c) black currant pip oil rich in  $\gamma$ -linolenic acid (polyunsaturated fatty acid 18:3 n-6) in a proportion of 10% by weight in the foodstuff;
- 15 (d) the combination of the above three products.

**2-B- Results:**

The product (b), namely a soja extract rich in isoflavonoids did not prevent the "testosterone effect" as observed in the context of the control experiments (Example 1-B), as illustrated in Figure 2 by the "control" curves and "soja extract enriched with a 40% content of isoflavones".

On the other hand, it emerges from Figure 2 that the products (a) and (c) as well as the combination of the products (a), (b) and (c), considerably reduced the difference in size between the right CVO and the left CVO.

25 The curve observed with the natural aroma of red wine (product (a)) retains, however, an upward slope, suggesting that the "testosterone effect" although advantageously slowed down, remained capable of a change with time contrary to the effect desired.

30 The curve observed with the product (c), corresponding to the oil containing polyunsaturated fatty acids, reflects a particularly strong, even sudden, inhibitory activity of the "testosterone effect" as from about day 20 of

administration. The disadvantage linked to the use of the product (c) alone results from the fact that the difference in size between the right and left CVOs was increased compared with the controls ("controls" curve) during about the first five days of treatment.

- 5           Ultimately, only the combination of the products (a), (b) and (c), corresponding to a composition containing polyunsaturated fatty acids, flavonoids and stilbenes in conformity with the present invention, made it possible to observe the anticipated inhibition profile, namely a considerable reduction of the "testosterone effect" as from the start of the treatment,  
10 followed by a progressive slowing down of said effect, in order to finally tend in the course of time towards a zero or practically zero effect.

          In addition, no effect of the different compounds tested, alone or in combination, has been demonstrated on the sexual organs of the male animals. In fact, it was observed that the various products tested did not  
15 adversely affect the weight of the seminal vesicles and the prostate (results not shown). These observations indicate that a cosmetic composition in conformity with the invention ought not to present undesirable side effects of the compositions already known.

20   **Example 3: Preparation of a composition according to the invention –  
Examples of formulation:**

**3-A- Formulation of the sugar-coated type:**

          The quantities of the different compounds are indicated in mg per  
25 sugar-coated tablet.

*Excipient of the coating core:*

- microcrystalline cellulose	70
- Encompress <sup>TM</sup>	60
- magnesium stearate	3
30 - anhydrous colloidal silica	1

*Coating agent:*

	- gum-lac	5
	- talc	61
	- sucrose	250
	- polyvidone	6
5	- titanium dioxide	0.3
	- coloring agent	5

*Active ingredient:*

	- black currant pip oil	0.5
	- red wine extract containing 18% polyphenols	2
10	- soja extract enriched with 40% content of isoflavones	2

A unit dose in the sense of the invention corresponds in kind to one sugar-coated tablet.

3-B- Formulation of the plant or animal gelatine capsule type:

15 The quantities of the different compounds are indicated in mg per capsule

*Excipient:*

	- starch	128
	- magnesium stearate	2.5

20 *Active ingredient:*

	- black currant pip oil	200
	- red wine extract containing 18% of polyphenols	100
	- soja extract enriched with 40% content of isoflavones	50

25 The unit dose as defined in the preceding description corresponds to one capsule.

3-C- Formulations of the unidose gel type:

The following quantities are expressed in % of the total weight of the final product.

30 According to this formulation, the unit dose is equivalent to 200 ml  
≈200 g

a) Unidose gel 1:*Excipient:*

	- sugar syrup	30
	- maltodextrin	17
5	- xanthan gum	0.8
	- sodium benzoate	0.2
	- water	qsp 100

*Active ingredient:*

	- black currant pip oil	20
10	- red wine extract containing 18% of polyphenols	10
	- soja extract enriched with 40% content of isoflavones	20

a) Unidose gel 2:*Excipient:*

15	- sugar syrup	50
	- maltodextrin	17
	- xanthan gum	0.8
	- sodium benzoate	0.2
	- water	qsp 100

## 20 Vitamins and trace elements:

	- anti-oxidant complex	*
--	------------------------	---

*Active ingredient:*

	- black currant pip oil	10
	- red wine extract containing 18% of polyphenols	12
25	- soja extract enriched with 40% content of isoflavones	24

\* The anti-oxidant complex contains in 200 ml of gel:

	- vitamin C	120 mg
	- selenium	100 µg
	- vitamin E	30 mg
30	- zinc	20 mg
	- β-carotene	6 mg

### 3-D- Formulation of capsule type:

The following quantities are expressed in mg per capsule.

According to this formulation, a unit dose corresponds to a capsule.

#### 5                    a) Capsule 1:

*Excipient:*

- glycerol	150
- magnesium stearate	0.02
- water	qsp 900

#### 10        *Trace element:*

- zinc gluconate	160
------------------	-----

*Active ingredient:*

- black currant pip oil	300
- red wine extract containing 18% of polyphenols	200
15    - soja extract enriched with 40% content of isoflavones	200

#### b) Capsule 2:

*Excipient:*

- glycerol	150
20    - magnesium stearate	0.02
- water	qsp 900

*Vitamins and trace elements:*

- vitamin complex	*
- zinc gluconate	160

#### 25        *Active ingredient:*

- black currant pip oil	400
- red wine extract containing 18% of polyphenols	100
- soja extract enriched with 40% content of isoflavones	300

\* The vitamin complex contains per capsule:

- vitamin C	60 mg
- selenium	50 µg
- vitamin E	15 mg
- zinc	10 mg
- lycopene	3 mg

3-E- Formulation of soft capsule type:

The following quantities are expressed in mg per soft capsule.

*Excipient:*

- soja oil	40
- wheat germ oil	85
- soja lecithin	25

*Vitamins:*

- natural tocopherols	3
- vitamin C	60

*Active ingredient:*

- black currant pip oil	200
- red wine extract containing 18% of polyphenols	100
- soja extract enriched with 40% content of isoflavones	100

Of the kind, a unit dose is equivalent to a soft capsule.

**CLAIMS**

1.     Cosmetic composition useful for the prevention and/or the correction of the functional disorders of the pilo-sebaceous unit of mammals and destined for administration by the oral route, characterized in that it contains polyunsaturated fatty acids, flavonoids and stilbenes.
2.     Composition according to Claim 1, characterized in that it is designed to combat the cutaneous activation of androgens, in particular, over the course of time.
3.     Composition according to Claim 1, characterized in that it is a food supplement.
4.     Composition according to Claim 1, characterized in that said mammals are domestic.
5.     Composition according to Claim 1, characterized in that said mammals are human beings.
6.     Composition according to any one of the Claims 1 to 3, characterized in that said polyunsaturated fatty acids and/or said flavonoids and/or said stilbenes are of natural origin.
7.     Composition according to any one of the Claims 1 to 3, characterized in that said polyunsaturated fatty acids, said flavonoids and said stilbenes are of natural origin.
8.     Composition according to the Claim 6 or 7, characterized in that said polyunsaturated fatty acids are of the group n-6.
9.     Composition according to Claim 8, characterized in that said polyunsaturated fatty acids correspond to  $\gamma$ -linolenic acid.

10. Composition according to Claim 8 or 9, characterized in that said polyunsaturated fatty acids are contained in an oil or an extract selected from black currant pip oil, evening primrose oil, borage oil, hemp oil, the extracts of spiruline, in particular *Spirula maxima* and *S. platensis*, and the oils of fishes and those derived from sea products, and preferably black currant pip oil.  
5
11. Composition according to Claim 6 or 7, characterized in that said flavonoids are isoflavonoids, preferably isoflavones.
12. Composition according to Claim 11, characterized in that said isoflavones are selected from daidzeine, genisteine and their mixture.  
10
13. Composition according to Claim 11 or Claim 12, characterized in that said flavonoids are contained in plant extracts, such as the vine, tea, fruits, soja and preferably soja.
14. Composition according to Claim 6 or 7, characterized in that said stilbenes are hydroxystilbenes.  
15
15. Composition according to Claim 14, characterized in that said hydroxystilbenes are selected from resveratrol and its derivatives, in particular the esters and glycosylated derivatives of the latter.
16. Composition according to any one of the Claims 14 to 15, characterized in that said stilbenes are extracts of the grape, in particular of grape skin and/or products derived from the grape, in particular wine.  
20
17. Composition according to any one of the Claims 1 to 3, 6 and 7, characterized in that it is packaged in the form of unit doses for an administration of 1 to 6 units per day, and preferably 3 units per day.  
25

18. Composition according to Claim 17, characterized in that it contains from 0.1 % to 99% by weight of polyunsaturated fatty acids per unit dose.
- 5 19. Composition according to Claim 18, characterized in that it contains from 5 to 60%, and preferably from 10 to 40% by weight of polyunsaturated fatty acids per unit dose.
20. Composition according to Claim 17, characterized in that it contains from 0.1 % to 99% by weight of flavonoids per unit dose.
- 10 21. Composition according to Claim 20, characterized in that it contains from 5 % to 60%, and preferably 10 to 30% by weight of flavonoids per unit dose.
22. Composition according to Claim 17, characterized in that it contains from 0.1 % to 99% by weight of stilbenes per unit dose.
- 15 23. Composition according to Claim 22, characterized in that it contains from 5 % to 40%, and preferably 10 to 25% by weight of stilbenes per unit dose.
24. Composition according to any one of the Claims 1 to 23, characterized in that it contains in addition at least one excipient appropriate for oral administration.
- 20 25. Composition according to any one of the Claims 1 to 24, characterized in that it contains in addition one or more vitamins and/or trace elements.
- 25 26. Cosmetic method for the prevention and/or correction of the functional disorders of the pilo-sebaceous unit of mammals, in particular of human and domestic animals, consisting of administering a

composition according to any one of the Claims 1 to 25 by the oral route.

- 5 27. Procedure according to Claim 26, characterized in that said composition, packaged in a form of unit doses, is administered at a rate of 1 to 6 units per day, and preferably 3 units per day.
- 10 28. Use of a composition containing polyunsaturated fatty acids, flavonoids and stilbenes for the preparation of a food supplement designed to prevent and/or correct the functional disorders of the pilosebaceous unit of mammals, in particular of human and domestic animals.
29. Use according to Claim 28, characterized in that said polyunsaturated fatty acids and/or said flavonoids and/or said stilbenes are of natural origin.
- 15 30. Use according to Claim 28, characterized in that said polyunsaturated fatty acids, said flavonoids and said stilbenes are of natural origin.
31. Use according to Claim 29 or 30, characterized in that said polyunsaturated fatty acids are of group n-6, such as  $\gamma$ -linolenic acid.
- 20 32. Use according to Claim 29 or 30, characterized in that said flavonoids are isoflavonoids, preferably isoflavones, such as the isoflavones selected from daidzeine, genisteine and their mixture.
33. Use according to Claim 29 or 30, characterized in that said stilbenes are hydroxystilbenes selected from resveratrol and the derivatives of the latter, in particular the esters and glycosylated derivatives of the latter.

34. Use according to Claim 28, characterized in that said composition is packaged in the form of unit doses for an administration of 1 to 6 units per day, and preferably 3 units per day, by the oral route.
- 5 35. Use according to Claim 34, characterized in that said composition contains 0.1% to 99% by weight of polyunsaturated fatty acids per unit dose.
36. Use according to Claim 35, characterized in that said composition contains from 5 % to 60%, and preferably from 10 to 40% of polyunsaturated fatty acids per unit dose.
- 10 37. Use according to Claim 34, characterized in that said composition contains 0.1% to 99% by weight of flavonoids per unit dose.
38. Use according to Claim 37, characterized in that said composition contains 5 to 60%, and preferably from 10% to 30% by weight of flavonoids per unit dose.
- 15 39. Use according to Claim 34, characterized in that said composition contains 0.1% to 99% by weight of stilbenes per unit dose.
40. Use according to Claim 39, characterized in that said composition contains 5 to 40%, and preferably from 10 to 25% by weight of stilbenes per unit dose.

1 / 2




Figure 1

2 / 2




Figure 2